137 related articles for article (PubMed ID: 38669544)
21. The Effect of Gender and APOE ɛ4 Status on Brain Amyloid-β Deposition in Different Age Groups of Mild Cognitively Impaired Individuals: A PET-CT Study.
Wang J; Wang M; Ren S; Huang L; He K; Li J; Hua F; Guan Y; Guo Q; Huang Q; Xie F
J Alzheimers Dis; 2023; 94(2):763-775. PubMed ID: 37334590
[TBL] [Abstract][Full Text] [Related]
22. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
23. Comparing predictors of conversion and decline in mild cognitive impairment.
Landau SM; Harvey D; Madison CM; Reiman EM; Foster NL; Aisen PS; Petersen RC; Shaw LM; Trojanowski JQ; Jack CR; Weiner MW; Jagust WJ;
Neurology; 2010 Jul; 75(3):230-8. PubMed ID: 20592257
[TBL] [Abstract][Full Text] [Related]
24. APOEɛ4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment.
Hobel Z; Isenberg AL; Raghupathy D; Mack W; Pa J;
J Alzheimers Dis; 2019; 71(2):647-658. PubMed ID: 31424388
[TBL] [Abstract][Full Text] [Related]
25. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
[TBL] [Abstract][Full Text] [Related]
26. Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.
Duff K; Suhrie KR; Hammers DB; Dixon AM; King JB; Koppelmans V; Hoffman JM
Clin Neuropsychol; 2023 Jan; 37(1):157-173. PubMed ID: 34713772
[TBL] [Abstract][Full Text] [Related]
27. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
[TBL] [Abstract][Full Text] [Related]
28. The Associations Between Serum Insulin-like Growth Factor-I, Brain White Matter Volumes, and Cognition in Mild Cognitive Impairment and Alzheimer's Disease.
Horvath A; Quinlan P; Eckerström C; Åberg ND; Wallin A; Svensson J
J Alzheimers Dis; 2024; 99(2):609-622. PubMed ID: 38701139
[TBL] [Abstract][Full Text] [Related]
29. Semantic memory activation in amnestic mild cognitive impairment.
Woodard JL; Seidenberg M; Nielson KA; Antuono P; Guidotti L; Durgerian S; Zhang Q; Lancaster M; Hantke N; Butts A; Rao SM
Brain; 2009 Aug; 132(Pt 8):2068-78. PubMed ID: 19515831
[TBL] [Abstract][Full Text] [Related]
30. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
31. Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment.
Cechova K; Andel R; Angelucci F; Chmatalova Z; Markova H; Laczó J; Vyhnalek M; Matoska V; Kaplan V; Nedelska Z; Ward DD; Hort J
J Alzheimers Dis; 2020; 73(1):247-257. PubMed ID: 31771052
[TBL] [Abstract][Full Text] [Related]
32. The Role of MRI Biomarkers and Their Interactions with Cognitive Status and APOE ε4 in Nondemented Elderly Subjects.
Liang X; Yin Z; Liu R; Zhao H; Wu S; Lu J; Qing Z; Wei Y; Yang Q; Zhu B; Xu Y; Zhang B
Neurodegener Dis; 2018; 18(5-6):270-280. PubMed ID: 30673663
[TBL] [Abstract][Full Text] [Related]
33. Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC).
Barker W; Quinonez C; Greig MT; Behar R; Chirinos C; Rodriguez RA; Rosselli M; Rodriguez MJ; Cid RC; Rundek T; McFarland K; Hanson K; Smith G; DeKosky S; Vaillancourt D; Adjouadi M; Marsiske M; Ertekin-Taner N; Golde T; Loewenstein DA; Duara R
J Alzheimers Dis; 2021; 79(1):59-70. PubMed ID: 33216030
[TBL] [Abstract][Full Text] [Related]
34. Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.
Bernath MM; Bhattacharyya S; Nho K; Barupal DK; Fiehn O; Baillie R; Risacher SL; Arnold M; Jacobson T; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; Kaddurah-Daouk R; Saykin AJ;
Neurology; 2020 May; 94(20):e2088-e2098. PubMed ID: 32358220
[TBL] [Abstract][Full Text] [Related]
35. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
36. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
37. 18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population.
Zhao Z; Wang J; Wang Y; Liu X; He K; Guo Q; Xie F; Huang Q; Li Z
J Alzheimers Dis; 2023; 93(2):585-594. PubMed ID: 37066915
[TBL] [Abstract][Full Text] [Related]
38. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
39. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
40. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
